Board
Our Board of Directors has been selected on their individual skills and contribution to Pacific Edge
Members of the Board of Directors represent a wide range of business skills, a deep rooted understanding of the global financial environment and broad experience in biomedical start-ups and the global biomedical marketplace.
| Name | Position | Appointed |
|---|---|---|
| Simon Flood | Chairman | 2025 |
| Anatole Masfen | Director | 2008 |
| Sarah Park | Director | 2018 |
| Bryan Williams | Director | 2013 |
| Anna Stove | Director | 2021 |
| Tony Barclay | Director | 2022 |
Simon Flood
Simon holds a BCom from the University of Canterbury and has spent more than 25 years in the global investment management industry having held senior Investment and Business Leadership roles in some of the world’s pre-eminent investment management firms.
His global perspective was honed through his years as a senior business leader and investor while working in London, Hong Kong and Singapore managing businesses, portfolios and teams of investors managing money on behalf of institutional investors from both the private as well as public sectors. Simon was a Managing Director at Merrill Lynch Investment Managers and COO of their Asian Business. He was Chief Investment Officer at Lion Global Investors, and prior to returning to New Zealand he was Head of Asia for AXA Investment Managers.
As an investor, Simon has had responsibility for the analysis and investment in listed equities, fixed income and has also had experience in the commercialisation of intellectual property and early-stage investment. While an analyst and portfolio manager Simon developed a keen interest in the global healthcare industry and has maintained that interest and knowledge base throughout his career.
Having returned to New Zealand in 2015, Simon has been appointed to several Boards and is currently the Chair of Queenstown Airport and is on the board of a number of other companies and foundations covering sectors of significance in the New Zealand economy.
Anatole Masfen
Anatole is the co-founder of Artemis Capital, a private equity investment firm based in Auckland. He graduated from the University of Auckland with an MCom (Hons) in Finance and Economics. Following that he spent eight years with Air New Zealand (and later the merged entity with Ansett Australia) holding senior positions in Pricing, Revenue Management and Systems implementation. He holds directorships in numerous private companies and has significant knowledge of financial capital markets. As a long standing director of PEB and investor in numerous medical and tech companies, Anatole has an a detailed knowledge of the medical sector and future trends. In particular human sciences and disruptive technologies.
Sarah Park
Sarah is the co-founder of Even Capital, a pioneering venture capital firm 100% focused on investing in female entrepreneurs in New Zealand and Australia. As an investor, Sarah has a passion for early stage businesses building world-changing technologies. Sarah brings 25+ years international corporate finance and capital markets experience to Pacific Edge after a professional career with PwC in NZ and HSBC Investment Bank in London. During her executive career, Sarah held a wide variety of roles including advising on M&A and capital market transactions, managing family office investments, and as a sell-side Equity Research Analyst. Sarah is Deputy Chair of National Provident Fund, and a Director of NZ med-tech company, Orbis Diagnostics. Sarah has a MA(Hons) in Economics from the University of Edinburgh and is a member of the New Zealand Institute of Directors and Chapter Zero NZ.
Bryan Williams
Bryan is an internationally recognised cancer researcher and research administrator, with significant business experience. He has held a number of governance roles, including with a NASDAQ listed biotech company. Presently, he serves on boards of two Australian and one American privately held biotechnology companies. He is also a co-founder of an American biotechnology company. Bryan was Director and CEO of the Hudson Institute of Medical Research. He is currently Emeritus Director and Distinguished Scientist at the Hudson Institute in Melbourne. He has a BSc (Hons) and PhD in Microbiology from the University of Otago.
Anna Stove
Anna has a successful track record in leading and driving transformational change within the Healthcare sector. She has significant Global business experience having held a variety of senior executive roles within Asia Pacific and Europe. Prior to stepping down from corporate life, Anna was the NZ General Manager of GlaxoSmthKline. She is now committed to growing businesses through best practice governance. Anna also Chair’s Rua Bioscience.
Tony Barclay
Tony brings over 30 years experience in business and 22 years healthcare experience. Tony was CFO at medical device company Fisher & Paykel Healthcare from the time of separation from Fisher & Paykel Appliances in 2001 until retiring from full-time employment in 2018. Prior to Fisher & Paykel Healthcare Tony worked for PriceWaterhouse and Arnott's Biscuits in finance roles. Tony is also a board member of listed company Rua Bioscience and holds a number of directorships in private companies, all in MedTech. Tony holds a BCom from the University of Otago and is a Chartered Accountant and a member of the New Zealand Institute of Directors and INFINZ.
Patent Portfolio
Pacific Edge utilises experienced patent attorneys in both NZ and the US to support our intellectual property strategies
Our suite of intellectual property »
Innovative Solutions
Our products support the early diagnosis and better management of cancer
